The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update

The international, phase III, multi-centre AZA-001 trial demonstrated azacitidine (AZA) is the first treatment to significantly extend overall survival (OS) in higher risk myelodysplastic syndromes (MDS) patients (Fenaux (2007) Blood 110 817). The current treatment paradigm, which is based on a rela...

Descripción completa

Detalles Bibliográficos
Autores principales: Silverman, LR, Fenaux, P, Mufti, GJ, Santini, V, Hellström-Lindberg, E, Gattermann, N, Sanz, G, List, AF, Gore, SD, Seymour, JF, Backstrom, J, McKenzie, D, Beach, CL
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2008
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234059/
https://www.ncbi.nlm.nih.gov/pubmed/22275990
http://dx.doi.org/10.3332/ecancer.2008.118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234059/
https://www.ncbi.nlm.nih.gov/pubmed/22275990
http://dx.doi.org/10.3332/ecancer.2008.118

Ejemplares similares